| Name | Title | Contact Details |
|---|
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
MedPro Systems is a Mount Arlington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Karl Storz industrial products are manufactured to the highest world standards and supported by a highly trained Customer Service team.
Reach Fitness Club is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
NantHealth is a transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system. NantHealth solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical and operational delivery with real time actionable clinical data, and promoting wellness for a healthier, happier world. We are building an integrated, evidence-based, omically-informed, personalized approach to the delivery of care and the development of next generation healthcare solutions. NantHealth is a subsidiary of NantWorks a company founded and led by Dr. Patrick Soon-Shiong. NantWorks is a convergence of next generation machine vision, object and voice recognition technologies, ultra-low power semiconductors, supercomputing, and advanced networks for the purpose of bringing the digital revolution to healthcare, commerce, and digital entertainment to an entirely new level. NantHealth envisions a world in which cutting-edge developments in science, technology, infrastructure and human ingenuity converge to advance one extraordinary mission: transforming healthcare for the benefit of every patient. We merge innovation with infrastructure; empowering more efficient and effective clinical decisions through advanced and actionable health information. By improving the accuracy and timeliness of data, we can deliver targeted healthcare intelligence for evolutionary personalized care. Our ultimate mission is to empower progress through uniquely informed decisions; to bring the impossible to life by harnessing the power of convergence for the well-being of humanity.